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Abstract 
The  diagnosis  of  neuroborreliosis  is  not
always  straightforward.  Intrathecal
immunoglobulin  (Ig)  synthesis  against
Borrelia antigen may not be detected, at least
early in the disease course. Also other neuro-
logical  and  infectious  diagnoses  have  to  be
considered.  We  have  studied  patients  with
clinical  possible  neuroborreliosis  without
intrathecal Ig synthesis against Borrelia anti-
gen in the cerebrospinal fluid (CSF) (n=17).
Diagnosis was based on typical clinical history
and  at  least  one  of  the  following  findings;
mononuclear leucocytosis in the CSF (n=4);
typical erythema migrans >5 cm in diameter in
relation to debut of symptoms (n=8); prompt
clinical  response  to  antibiotic  teratment
(n=14). Also other possible diagnoses had to
be excluded. Seventeen patients first investi-
gated  because  of  suspected  neuroborreliosis
but later confirmed with other diagnoses were
used  as  controls.  All  patients  had  a  lumbar
puncture.  Borrelia  specific  IFN-ʳ and  IL-4
secretion was investigated in peripheral blood
(PBL)  and  CSF  with  an  ELISPOT  assay.
Polymerase chain reaction (PCR) was used to
reveal any Borrelia antigen in the CSF. Six of
17  patients  with  possible  neuroborreliosis
showed  high  IFN-ʳ secretion  in  peripheral
blood, otherwise we found no statistically sig-
nificant differences between the groups. PCR
did not reveal any Borrelia antigen in CSF. The
diagnosis  and  treatment  of  possible  but  not
confirmed neuroborreliosis is a clinical chal-
lenge. The clinical response to treatment may
be the best option in these cases. 
Introduction
Borrelia can affect many organ systems, i.e.
skin,  heart,  joints  and  the  nervous  system.1
Clinical symptoms are variable and depend on
the subtype of Borrelia. Borrelia burgdorferi
sensu  latu  typically  cause  arthritis.  Borrelia
garinii mainly causes neurological symptoms2
whereas Borrelia afzelii give rise to the erythe-
ma chronicum migrans, common for all three
subtypes.
The neurological symptoms are not specific
for  neuroborreliosis  but  may  occur  in  many
other  neurological  diseases.3 This  makes  the
clinical diagnosis difficult unless there is a pre-
ceding  erythema  migrans.  Also  laboratory
parameters  to  diagnose  neuroborrelia  are
uncertain  because  of  a  late  and  inconsistent
occurrence  of  antibodies  against  Borrelia.
Intrathecal synthesis of Borrelia antibodies is of
diagnostic importance4 and so is mononuclear
leucocytosis  in  the  cerebrospinal  fluid  (CSF)
and  signs  of  blood-brain  barrier  damage.5
Polymerase  chain  reaction  (PCR)  has  been
utilised in several studies but is not routinely
recommended due to the limited clinical sensi-
tivity of this method.6,7 When the diagnosis of
neuroborreliosis  is  confirmed  or  highly  likely
treatment with antibiotics is initiated. Usually
neurological symptoms are reduced and eventu-
ally disappear. Some patients, however, experi-
ence  reappearing  or  persistent  neurological
symptoms some time after the treatment.1 It is
not clear if these late-symptoms are related to
persistent symptoms of an Borrelia infection or
if they are caused by other neuroimmunological
reactions or both. Persistent symptoms may also
be due to irreversible damage of the nervous sys-
tem. The purpose of our study was to investigate
patients with clinical possible neuroborreliosis
but lacking intrathecal synthesis of antibodies
against  Borrelia  antigen.  In  clinical  practice
there is a need for other methods to discrimi-
nate true neuroborreliosis patients from other
with  mimicking  symptoms  and  laboratory
parameters. We aimed at looking for levels of the
type 1 cytokine IFN-ʳ and the type 2 cytokine IL-
4 in CSF and blood.
Materials and Methods
Patients and controls
Clinical  and  laboratory  supported  definite
neuroborreliosis8 is  characterized  as;  typical
clinical  neurological  symptoms  (meningitis,
cranial neuritis, or radiculitis), CSF mononu-
clear leucocytosis and intrathecal synthesis of
Borrelia  specific  antibodies  (Daco  kit  for
detection of anti-flagellin antibodies in serum
and CSF was used).9 We identified a subgroup
of patients with typical neurological symptoms
without intrathecal synthesis of Borrelia spe-
cific antibodies (n=17, 9 women and 8 men,
mean age 50.5 years) but with intrathecal leu-
cocytosis (n=4), erythema migrans in relation
to symptoms (n=8) and/or response to antibi-
otic treatment (n=14), referred to as possible
neuroborreliosis.  Eleven  of  the  17  patients
with  possible  neuroborreliosis,  however,
showed positive serology for IgG and/or IgM
against Borrelia in serum. Seventeen patients
first  investigated  because  of  suspected  neu-
roborreliosis  but  later  confirmed  with  other
diagnoses were used as controls (8 women and
9 men, mean age 44.5 years). Characteristics
of the patients are shown in Table 1.
Preparation of mononuclear cells
from blood and cerebrospinal fluid
Blood (heparinized) and CSF samples were
obtained  from  patients  with  suspected  NB.
Peripheral  blood  mononuclear  cells  (PBMC)
were separated by gradient centrifugation on
Lymphoprep® (Medinor  AB,  Stockholm,
Sweden) at 400 g for 30 minutes in room tem-
perature,  according  to  Bøyum.10 Cells  were
counted  under  a  phase-contrast  microscopy
using a Bürker chamber, and the lymphocyte
concentration was adjusted to 1ﾥ106/mL. CSF-
cells  were  counted  using  phase-contrast
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Table 1. Characterization of patients with possible neuroborreliosis without intrathecal Ig-synthesis against Borrelia antigen in the cere-
brospinal fluid and controls with other diagnosesPat.
No. Diagnosis Sex Age Tick EM Duration Borrelia CSF Sp/s  Intra-thecal Symptoms Antibiotic Clinical
years bite of symp-toms serologya MNCb alb total IgG- therapye response
(days) IgG  IgM ratioc synthesisd to antibiotic
therapy
1 NB F 66 -- 43 +         - +N + Paresthesia,  Tetracycline +
dysesthesia
2 NB F 51 ++ 17 +         + -N - Headache,  Tetracycline +
numbness,
arthralgia, fatigue
3 NB M 43 ++ 120 -          - -N -Fatigue, headache,  Penicillin-V +
paresthesia
4 NB F 48 ++ 30 +         - -+ - Headache, radiculitis, Ceftriaxone +
vertigo, double-vision
5 NB F 30 ++ 30 +         - -+ ND Headache, fatigue Tetracycline -
6 NB M 78 -+ 45 -          - -+ -Numbness in the leg tetracycline +
7 NB M 65 +- 45 -          - +N +Fever, paresthesia,  Tetracycline +
headache
8 NB M 34 ++ 60 -          + -+ - Fatigue, vertigo,  Penicillin-V +  +
headache tetracycline
9 NB F 65 ++ 14 -          - -+ - Facial paresis, neck pain Teracycline +
10 NB M 58 -- 270 +         - -N - Fatigue, vertigo,  Tetracycline +
leg weakness, radiculitis
11 NB F 42 -- 60 +         + -+ + Facial paresis,  Tetracycline +
numbness in 
half side of the face
12 NB F 55 -- 30 +         - -N - Facial paresis, radiculitis Tetracycline +
13 NB F 40 ++ 6 +         - -N - Myalgia, fatigue, headache Penicillin-V -
14 NB M 68 +- 14 -          - +N - Facial paresis, neck pain Tetracycline +
15 NB M 38 +- 30 +         - -+ - Facial paresis, fatigue Tetracycline +
16 NB F 47 +- 360 -          - -N -Sensory disturbance  Ceftriaxone +
in the foot
17 NB M 30 -- 10 years +         - +N + Paresthesia, numbness -
18 MS M 40 -- 4 -          - -+ + Arm weakness -
19 MS F 24 -- 60 -          - -N - Facial paresis, numbness  -
in the feet
20 Facial palsy M 52 +- 6 -          - -N - Facial paresis, vertigo -
21 Facial palsy F 57 -- 7 -          - -N - Facial paresis -
22 Facial palsy F 51 +- 60 -          - -N - Facial paresis. fatigue -
23 Fatigue M 37 +- 150 -          + -+ - Fatigue, concentration  -
problem
24 Fatigue M 36 +- 180 +         + -N -Fatigue, paresthesia Tetracycline -
25 Myalgia F 48 +- 70 -          + -N - Migrating muscle pain,  -
low back pain
26 Headache F 56 -- 240 -          + -N -Headache, vertigo,  -
paresthesia, fatigue
27 Vestibular  F 69 -- 2.5 years +         - -N ND vertigo -
neuritis
28 Collagenosis M 53 -- 67 -          + -N - Fatigue, myalgia,  Tetracycline -
arthralgia
29 Meningitis M 53 +- 90 -           - ++ - Facial paresis, vertigo,  -
eye pain, nystagmus
30 Paresthesia F 26 -- 60 -          + -N -Transient numbness  -
in one arm
31 Comotio  M 29 -- 60 -           - -+ - Paresthesia in both hands -
medullae 
spinalis
32 Compression M 35 +- 120 +          - -N - Paresthesia and transient  -
of thoracal  weakness of  one leg
vertebrae
33 Cerebral  F 45 -- 14 -           - +N - Headache, paresthesia,  Ceftriaxone -
infarction dysarthria
34 Panic syndrome M 46 -- 20 -           - -N - Vertigo -
MS, multiple sclerosis; EM, erythema migrans in relation to symptoms; N, normal; ND, not done; F, female, M, male. Duration of symptoms in days if not stated otherwise. a+= patients positive in the Borrelia ELISA
for IgG or IgM in blood. bMononuclear leucocytosis in the cerebrospinal fluid ≥5ﾥ106/L. cSpinal/serum albumin ratio (Sp/s alb ratio) (+=elevated). d+=IgG index ≥0.7. eTetracycline was given as an oral dose of 200
mg daily for 14 days; penicillin-V 2 gr orally daily for 10 days; ceftriaxone 2 gr intravenously daily for 14 days.microscopy, by use of a Jessen chamber, before
undergoing  10  minutes  of  centrifugation  at
200 g at 4ºC, followed by gentle resuspension
in cell culture medium (TCM).
Preparation of outer surface pro-
tein fraction Borrelia antigen
An  outer  surface  protein  (osp)  enriched
fraction  (OF),  mainly  containing  OspA  and
OspB, was prepared from of Borrelia garinii
strain  Ip90,  as  previously  described.11-13 OF
stimulation of PBMC and CSF-MNC was shown
in  adults  to  discriminate  between  patients
with neuroborreliosis and patients with other
neurological diseases as well as healthy con-
trols in the IFN ʳ and IL 4-ELISPOT-assay.14,15
ELISPOT for analysis of IL-4 and
IFN-ʳ producing cells
The  ELISPOT  assay,  which  was  originally
described by Czerkinsky et al.,16 was used for
analysis  of  Borrelia  (OF)-stimulated  and
unstimulated  cytokine  secreting  cells.  The
method was slightly modified and optimized
for IL-4 and IFN-ʳ spots as described previous-
ly.11-13 The spots were counted under a dissec-
tion  microscope.  One  spot  resembles  one
cytokine secreting cell.
DNA extraction and polymerase
chain reaction amplification
A QIAamp tissue kit (Qiagen) was used for
DNA extraction according to the protocol of the
manufacturer. Samples were eluted with 50 mL
of AE buffer and stored in – 20°C. For detection
of Borrelia antigen the 16S rRNA sequence was
amplified by a nested PCR. Primers16S-F and
16S-R and LD1 and LD2 were used in the ampli-
fication. The products were visualized by elec-
trophoresis in a 1.5% agarose gel stained with
ethidium bromide. A negative control and a pos-
itive control were included in all PCR runs. The
method is previously described by us.17
Data handling and statistics
The mean of triplicates or duplicates was
used  in  the  analysis  of  cytokine  results.  To
determine Borrelia specific secretion, the num-
ber of spots in the unstimulated wells was sub-
tracted from the number in the OF-stimulated
wells. For CSF-cells, data were recalculated to
the number of spots/100 000 lymphocytes. For
comparison of cytokine secreting cell counts
between multiple groups or intervals, Kruskal-
Wallis  was  used  as  a  pre-test,  and  Mann-
Whitney U test as post-hoc. P<0.05 were con-
sidered significant.
The  present  study  was  approved  by  the
ethics  committee  of  the  Faculty  of  Health
Sciences at Linköping University (Linköping,
Sweden). Informed consent was obtained from
each of the patients included in the study.
Results
Six of 17 patients with possible neuroborrelio-
sis had the highest IFN-ʳsecretion in peripheral
blood  upon  Borrelia  antigen  stimulation.  The
median values between the groups were not sta-
tistically significant, however. We found no dif-
ferences in IL-4 or IFN-ʳ secretion in the CSF
(Table 2 and Figure 1). PCR did not reveal any
Borrelia antigen in CSF.
Borrelia serology in blood seems unspecific
and could mirror an earlier infection or in case of
IgM antibodies be an unspecific reaction (10 had
IgG and 3 IgM of the neuroborreliosis patients
and 3 had IgG and 6 IgM of the controls). Also
mononuclear leucocytosis in the CSF, blood-brain
barrier damage, and intrathecal immunoglobulin
synthesis were seen in both possible neuroborre-
liosis patients and controls with other diagnoses.
In the control group mononuclear leucocytosis in
the  CSF  was  seen  in  one  patient  with  viral
meningitis  and  one  with  cerebral  infarction;
blood-brain barrier damage in one patient with
multiple sclerosis (MS), fatigue, viral meningitis
and  comotio  medullae  spinalis,  respectively;
intrathecal immunoglobulin synthesis in one MS
patient.
Symptoms are often non-specific such myal-
gia, paresthesia, fatigue and headache and were
reported equally in the possible neuroborreliosis
patients and controls with other diagnoses. In
the  control  group  3  patients  with  facial  palsy
(Bells palsy) and 3 with unspecific fatigue or
myalgia and 1 with transient paresthesia and 1
with tension headache without preceding erythe-
ma migrans or mononuclear leucocytosis in CSF
were included. Otherwise the diagnoses in the
control group were diverse but specific (Table 1).
The most reliable clinical feature of a possible
neuroborreliosis  was  a  preceding  erythema
migrans in 8 out of 17 patients in contrast to
none of the 17 controls. Tick bite did not discrim-
inate between the groups.
Clinical response to antibiotic treatment was
seen in 14 out of 16 treated patients with possi-
ble neuroborreliosis (12 were treated with tetra-
cycline 200 mg orally for 14 days; 2 with ceftriax-
one 2gr iv for 14 days; 3 with penicillin-V 2 gr
orally for 10 days, one of which also treated with
tetracycline) and could be taken as an indication
of at least an infectious etiology. Patient no 5 and
13 in table 1 did not respond to treatment. The
first patient had persistent headache and fatigue
after  tetracycline  treatment  and  the  second
patient was treated early after debut of symptoms
(6 days) and received only penicillin-V orally. In
the control group 3 patients were treated on the
early suspicion of neuroborreliosis (2 with tetra-
cycline and one with ceftriaxone) but later con-
firmed with other diagnoses.
Patient no 10, 12, 15, and 16 were judged as
possible neuroborreliosis (Table 1) because of
typical neurological symptoms (2 radiculitis, 1
facial palsy and one with a radicular distribution
of sensory disturbance in the foot) and prompt
response  to  antibiotic  treatment.  These  4
patients, however, did not report any erythema
migrans or had any CSF findings (except one
with a non-specific elevated spinal/serum albu-
min-ratio).
One patient (no 17) judged as possible neu-
roborreliosis was not treated because of long-
lasting symptoms (10 years). These patients are
referred  to  as  post-Lyme  disease  syndrome
(PLDS) and therapy has no clear impact of the
symptoms. Three of our patients with possible
neuroborreliosis had their symptoms for more
than 6 months, often classified as late neurobor-
reliosis,18 but the majority of our patients had
early possible neuroborreliosis.
Discussion
The  most  common  diagnostic  tool  to  the
diagnosis of neuroborreliosis is ELISA analysis
for antibodies against the Borrelia antigen. We
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Table 2. Net secretion of IFN-ʳ and IL-4 spots in patients with possible neuroborreliosis
and patients with other diagnoses.
Diagnosis N Mean rank Pa
Net IFN-ʳin PBL Neuroborreliosis 15 16.7 0.12
Spots/100 000 cells Other diagnosis 13 11.9
Total 28
Net IL-4 in PBL Neuroborreliosis 15 15.9 0.33
Spots/100 000 cells Other diagnosis 13 12.9
Total 28
Net IFN-ʳin CSF Neuroborreliosis 12 12.10 0.72
Spots/100 000 cells Other diagnosis 10 11.0
Total 22
Net IL-4 in CSF Neuroborreliosis 8 6.4 0.54
Spots/100 000 cells Other diagnosis 3 5.0
Total 11
aMann-Whitneyused the Daco kit for detection of anti-flagellin
antibodies in serum and CSF, previously shown
to be a sensitive and specific test.19 None of
the 17 patients with possible neuroborreliosis
had antibody titers against the flagellin anti-
gen in CSF, but 11 had elevated IgG or IgM
titers  in  serum.  PCR  did  not  reveal  any
Borrelia  antigen  in  CSF  and  the  method  is
often regarded as of low sensitivity, especially
in blood and in late neuroborreliosis cases.18
The earliest indication of Borrelia infection
is usually erythema migrans.20 Eight patients
(47%)  with  possible  neuroborreliosis  had
noticed  an  erythema  migrans  in  relation  to
symptoms in the present study. Only 15 (14%)
of 106 patients with definite neuroborreliosis
had noted an erythema migrans in a previous
study.21 A  typical  erythema  migrans  with  a
diameter of >5 cm in conjunction with symp-
toms is usually regarded as more or less proof
of a Borrelia infection.22
Leucocytosis in the CSF is a common find-
ing in neuroborreliosis but may be a finding in
many  other  infectious  or  inflammatory  dis-
eases. All patients were lumbar punctured and
4  of  17  showed  leucocytosis  in  the  present
study. Also one patient with cerebral infarction
and one with viral meningitis showed leucocy-
tosis. We have previously shown that 85 of 106
patients with ELISA positive neuroborreliosis
had leucocytosis (5-2330ﾥ106/L) in the CSF. It
is possible that the lower number of patients
with  leucocytosis  in  the  CSF  in  the  present
study  reflects  a  weak  immune  response
against the Borrelia antigen. Another possibil-
ity is that the lumbar puncture was taken too
early in the disease process. Only 6 were taken
one month or earlier after the debut of symp-
toms, however. A diagnosis and treatment of
neuroborreliosis is not always straightforward
and proposed guidelines for the management
of this has recently been published.18,23
We previously showed a compartmentalized
interferon-gamma  (IFN-ʳ)  response  in  the
central nervous system (CNS) in patients with
neuroborreliosis15 and that an IFN-ʳ predomi-
nated  response  was  associated  with  a  good
prognosis in asymptomatic sero-positive indi-
viduals.24 In the present study we did not find
any significant difference in IFN- ʳ or IL-4 pro-
duction in the CSF, however. Recently elevated
levels  of  the  B-lymphocyte  attracting
chemokine (CXCL13) in the CSF in early neu-
roborreliosis patients have been found.25It has
also been seen in the CSF of multiple sclerosis
patients26 making  the  specificity  of  the  test
uncertain. Most of our patients with possible
neuroborreliosis were treatment with doxycy-
cline reported to have a downregulatory effect
on proinflammatory cytokines.27 If this has any
significant relevance is uncertain and further-
more little is known about the effects on the
IFN- ʳ or IL-4 responses.
The diagnosis and treatment of possible but
not  confirmed  neuroborreliosis  is  a  clinical
challenge. Even though we found the highest
IFN-ʳ levels in 6 out of 17 patients with possi-
ble neuroborreliosis in blood, the test is unspe-
cific and may be elevated also in other inflam-
matory  conditions.  Further  improvements  in
diagnostic  tests  are  warranted  to  establish
early diagnosis and to avoid late complications.
The clinical picture may raise the suspicion of
neuroborreliosis,  which  can  be  further
strengthened  by  a  preceding  erythema
migrans  and/or  elevated  mononuclear  cell
count in the cerebrospinal fluid. A pragmatic
approach has been put forward in patients with
Article
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Figure 1. Number of Borrelia specific IFN-ʳ and IL-4 secreting cells per 100.000 lympho-
cytes in cerebrospinal fluid and peripheral blood in patients with probable neuroborre-
liosis and patients with other diagnoses as measured by ELISPOT. The Borrelia specific
secretion was obtained by subtracting the number of spots in unstimulated wells from the
number in Borrelia OF-stimulated wells.possible neuroborreliosis, namely a favorable
response to antibiotic treatment.28 Our study
also  indicates  that  the  clinical  response  to
treatment may be the best option in patients
with possible neuroborreliosis.
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